ISZO Capital Management’s Lifecore Biomedical LFCR Stock Holding History

ISZO Capital Management’s Portfolio LFCR Stock Details LFCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-373,778	Closed	-$2.42M	–	13
2022 Q4	$2.42M	Sell	373,778 -1,156,874	-76%	-$9.53M	32.38%	1
2022 Q3	$13.6M	Sell	1,530,652 -710,742	-32%	-$7.23M	23.34%	2
2022 Q2	$22.3M	Buy	2,241,394 +64,445	+3%	+$638K	35.12%	2
2022 Q1	$6.93M	Buy	2,176,949 +251,638	+13%	+$2.8M	8.22%	3
2021 Q4	$21.4M	Buy	1,925,311 +276,791	+17%	+$2.69M	11.24%	4
2021 Q3	$15.2M	Buy	+1,648,520	New	+$17.9M	6.71%	3

Other funds holding LFCR

GRIM

Greenhaven Road Investment Management Greenwich, Connecticut $145M AUM 13.76% 1-Year Est. Return

Wynnefield Capital New York $148M AUM 32.71% 1-Year Est. Return

LPAM

Legion Partners Asset Management Los Angeles, California $138M AUM 53.69% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

CSC

Cove Street Capital El Segundo, California $76.6M AUM 36% 1-Year Est. Return

22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

TAM

Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return

VWA

Visionary Wealth Advisors O'fallon, Illinois $2.26B AUM 19.48% 1-Year Est. Return

ISZO Capital Management's LFCR Position: Q1 2023 in Review

ISZO Capital Management sold out of Lifecore Biomedical (LFCR) in Q1 2023, closing a stake of 373,778 shares — an estimated $2.42M sold.

ISZO Capital Management first reported a position in LFCR in Q3 2021 and held it in 6 quarters. The position peaked at $22.3M in Q2 2022. 82 funds tracked by Wall St. Rank hold LFCR as of Q1 2023.

ISZO Capital Management reported no remaining Lifecore Biomedical position as of Q1 2023 after selling out during the quarter.
ISZO Capital Management sold 373,778 Lifecore Biomedical shares in Q1 2023, an estimated $2.42M.
ISZO Capital Management first reported a position in Lifecore Biomedical in Q3 2021 and held it in 6 quarters.
ISZO Capital Management's Lifecore Biomedical position peaked at $22.3M in Q2 2022.
82 funds tracked by Wall St. Rank held Lifecore Biomedical as of Q1 2023.

Based on ISZO Capital Management's 13F filing for Q1 2023, filed 15 May 2023.